Inhibikase Therapeutics, Inc. (IKT) is currently trading at $1.63 with a Wall Street consensus price target of $5.55, implying potential upside of 240.5% over the next 12 months. 10 analysts currently cover IKT, with a consensus rating of Buy - 90% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $8.0, while the most cautious has a target of $1.5.
IKT operates in the Healthcare sector with a market capitalisation of $227M. The stock is down 16.4% year-to-date and is currently trading near the lower end of its 52-week range of $1.4 – $2.61.
Other Healthcare stocks with comparable size and valuation.
Upgrade/downgrade history for IKT, with each firm's 90-day track record across all stocks we track. See full firm rankings →
Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.
Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.
StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.
View Full Rankings →